Clinical use of array comparative genomic hybridization (aCGH) for prenatal diagnosis in 300 cases
- PMID: 19012303
- PMCID: PMC3665952
- DOI: 10.1002/pd.2127
Clinical use of array comparative genomic hybridization (aCGH) for prenatal diagnosis in 300 cases
Abstract
Objective: To evaluate the use of array comparative genomic hybridization (aCGH) for prenatal diagnosis, including assessment of variants of uncertain significance, and the ability to detect abnormalities not detected by karyotype, and vice versa.
Methods: Women undergoing amniocentesis or chorionic villus sampling (CVS) for karyotype were offered aCGH analysis using a targeted microarray. Parental samples were obtained concurrently to exclude maternal cell contamination and determine if copy number variants (CNVs) were de novo, or inherited prior to issuing a report.
Results: We analyzed 300 samples, most were amniotic fluid (82%) and CVS (17%). The most common indications were advanced maternal age (N=123) and abnormal ultrasound findings (N=84). We detected 58 CNVs (19.3%). Of these, 40 (13.3%) were interpreted as likely benign, 15 (5.0%) were of defined pathological significance, while 3 (1.0%) were of uncertain clinical significance. For seven (approximately 2.3% or 1/43), aCGH contributed important new information. For two of these (1% or approximately 1/150), the abnormality would not have been detected without aCGH analysis.
Conclusion: Although aCGH-detected benign inherited variants in 13.3% of cases, these did not present major counseling difficulties, and the procedure is an improved diagnostic tool for prenatal detection of chromosomal abnormalities.
Copyright (c) 2008 John Wiley & Sons, Ltd.
Conflict of interest statement
CONFLICT OF INTEREST STATEMENT
The Medical Genetics Laboratories of the Department of Molecular and Human Genetics at Baylor College of Medicine (BCM), where the authors are employed as trainees, staff or faculty members, offers extensive genetic laboratory testing and derives revenue from this activity. BCM currently uses oligonucleotide arrays manufactured by Agilent Technologies.
Figures
References
-
- ACOG. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol. 2007a;109:217–227. - PubMed
-
- ACOG. ACOG Practice Bulletin No. 88, December 2007. Invasive prenatal testing for aneuploidy. Obstet Gynecol. 2007b;110:1459–1467. - PubMed
-
- Ballif BC, Hornor SA, Sulpizio SG, et al. Development of a high-density pericentromeric region BAC clone set for the detection and characterization of small supernumerary marker chromosomes by array CGH. Genet Med. 2007;9:150–162. - PubMed
-
- Ballif BC, Rorem EA, Sundin K, et al. Detection of low-level mosaicism by array CGH in routine diagnostic specimens. Am J Med Genet A. 2006;140:2757–2767. - PubMed
-
- Barber JC. Terminal 3p deletions: phenotypic variability, chromosomal non-penetrance, or gene modification? Am J Med Genet A. 2008;146A:1899–1901. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
